Lying down to make money at the end of the day, pharmaceutical companies, drug generation how to live?

"Pharmaceutical Network Market Analysis" October 17, "strict investigation of power and money transactions, the establishment of a list of loss of trust, centralized procurement, cut off the chain of medical bribery benefits" this document was released, the content refers directly to the medical representatives and medical institutions between the illegal receipt of kickbacks and other improper transactions.
industry pointed out that receiving rebates for medicines and medical supplies can be said to be a common form of pharmaceutical bribery.
In response to this behavior, the State Health Insurance Administration has issued "guidance on the establishment of a credit evaluation system for pharmaceutical prices and recruitment", requiring all regions to establish and implement a credit evaluation system by the end of 2020, involving pharmaceutical commercial bribery and other 7 kinds of mis-trusted pharmaceutical enterprises will be included in the "black list" of disrelieving. The
opinion mentions that once the drug enterprises have acted in bad faith, they will face written warnings, relying on centralized procurement platform to prompt the purchaser of risk information, restrict or suspend the relevant drugs or medical supplies hanging network, limit or suspend the procurement of related drugs or medical supplies, disclose the disincouration information and other disposal measures, the disincepment involves the number of provinces to meet the prescribed conditions, will also be initiated by the National Health Insurance Administration pharmaceutical prices and tender procurement guidance center to launch a national joint disposal.
, the State Drug Administration organized the "Pharmaceutical Representative Filing Management Measures (Trial)" also clearly stated that pharmaceutical representatives may not assume the task of drug sales, the implementation of collection and processing of purchase and sale bills and other sales behavior.
In addition, the document clearly defines the main tasks of pharmaceutical representatives, including four aspects: formulating plans and programs for the promotion of pharmaceutical products, transmitting relevant information on pharmaceutical products to medical personnel, assisting medical personnel in the rational use of pharmaceutical products of the enterprise, and collecting and feedback on the clinical use of pharmaceutical products and hospital needs.
In addition, the results of the third batch of collection is currently landing in the whole country, from the "4 plus 7" collection pilot to the current to the third batch of collection, involving a total of 112 varieties, an average decline of 54%, the drug price false high moisture was greatly squeezed out.
the future drug will face the situation of normal collection, price decline has become a trend.
not only drugs, high-value consumables collection also has eyebrows.
crown vein bracket became the first variety to implement centralized strip procurement, the first year of the total amount of intentional procurement of 1.0747 million, or will affect the market of tens of billions of yuan.
release of the above-mentioned series of documents means that the days when drug companies and drug companies were lying down to make money in the past are over.
, how can pharmaceutical companies and drug agents live in the midst of change? In the industry's view, for pharmaceutical companies, with the normalization of mining, transformation into a major survival choice, in the generic drug profits will be reduced, innovation will become the key to its development, pharmaceutical companies need to put more energy into research and development.
At present, many domestic pharmaceutical companies have actually made efforts in research and development, such as Hengrui, Fosun, China Biology, Stone Pharmaceuticals, Shanghai Pharmaceuticals, Colum and other leading enterprises, their research and development expenditure in 2019 is more than 1 billion yuan, compared with previous years have increased to varying degrees.
for the pharmaceutical generation, the future for a long time is its career transformation of the "pain period", under the influence of volume procurement, some of the winning enterprises quickly disbanded the sales team.
does not mean that the profession of pharmaceutical generation is not needed, and in the future, as the market share of the hospital gradually increases, representatives of the hospital may flow to the off-court market.
changes, drug companies will either continue to look for new opportunities in pharmaceutical companies or switch businesses al completely.